Ginkgo Bioworks Holdings Inc (DNA)
0.4087
-0.01
(-2.92%)
USD |
NYSE |
Jun 20, 16:00
0.4008
-0.01
(-1.93%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Cash from Financing (Quarterly): -0.845M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.845M |
| December 31, 2023 | -0.632M |
| September 30, 2023 | -0.315M |
| June 30, 2023 | -1.381M |
| March 31, 2023 | -0.888M |
| December 31, 2022 | 97.76M |
| September 30, 2022 | -0.391M |
| Date | Value |
|---|---|
| June 30, 2022 | -0.843M |
| March 31, 2022 | -1.192M |
| December 31, 2021 | -11.04M |
| September 30, 2021 | 1.548B |
| June 30, 2021 | -2.123M |
| March 31, 2021 | -0.433M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.04M
Minimum
Dec 2021
1.548B
Maximum
Sep 2021
125.03M
Average
-0.843M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| Pacific Biosciences of California Inc | 6.553M |
| Teladoc Health Inc | 1.751M |
| Prime Medicine Inc | 157.33M |
| Inovio Pharmaceuticals Inc | -11.36M |
| Nektar Therapeutics | 42.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -89.26M |
| Cash from Investing (Quarterly) | -12.11M |
| Free Cash Flow | -322.24M |
| Free Cash Flow Per Share (Quarterly) | -0.0479 |
| Free Cash Flow to Equity (Quarterly) | -95.97M |
| Free Cash Flow to Firm (Quarterly) | -95.97M |
| Free Cash Flow Yield | -40.09% |